With September revenues reported we are looking at better than $14.5M for Q3. September's number gives us a $66M Annual Run Rate. The first two weeks of November should be an exciting time for SCRC.

RapiMeds adding to this and "rivaling" compound pharmacy as Mr. Schneiderman stated, will position SCRC as a $100M company.

BB, spot on again!

GO SCRC!!!